Glenmark Pharmaceuticals Inc

• 

  Glenmark, US-Based Particle Sciences To Develop Generic Cancer Drug

  Glenmark Pharmaceuticals on Monday said it has entered into an agreement with US-based Particle Sciences Inc to develop and market a generic version of Celgene's ABRAXANE, which is used in treatments of breast and lung cancers.

• 

  Glenmark Gets US FDA Final Nod for Anti-Bacterial Drug

  Glenmark Pharmaceuticals has received the final nod from the US health regulator for a generic version of anti-bacterial drug Zyvox. "Glenmark Pharmaceuticals Inc, USA, has been granted final approval by the US Food & Drug Administration (USFDA) for the Linezolid tablets, 600 mg," Glenmark Pharmaceuticals said in a statement.

• Court Bars Glenmark from Selling Copies of Merck Diabetes Drugs: Report

  The court has, however, allowed Glenmark to continue to sell existing inventory, the sources said.

• Glenmark Gets Tentative USFDA Nod for Generic Psoriasis Cream

  It said in a statement that Glenmark Pharmaceuticals Inc, USA, a subsidiary of the company, has been granted tentative approval by the United States Food & Drug Administration (USFDA) for Calcipotriene cream, 0.005 per cent.

• Glenmark Unit to Pay $25 Mn to Settle Pricing Case

  Pharmaceutical major Glenmark on Wednesday said its US subsidiary will pay $25 million to settle a pricing investigation there.

• Glenmark Gets US Regulatory Nod for Osteoporosis Drug

  Glenmark Pharmaceuticals on Tuesday said it has received the final approval from the US Food and Drug Administration (FDA) for sale of drugs meant to prevent post-menopause osteoporosis.

• Glenmark Gets FDA Nod to Sell Blood Pressure Drug

  Glenmark Pharmaceuticals on Thursday announced receipt of approval from the US Food and Drug Administration (FDA) to sell its generic version of AbbVie Inc's blood pressure drug Tarka in the American market.

• Glenmark Gets Final Nod From US Drug Regulator for Skin Cream

  Glenmark Generics Inc USA, the subsidiary of Glenmark Generics Ltd, has been granted final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Fluocinonide cream USP (0.1 per cent), Glenmark Pharmaceuticals said in a statement.

• Glenmark Pharma Posts Net Profit of Rs 43 Crore in Q4

  Glenmark Pharmaceuticals on Thursday posted a consolidated net profit of Rs 43.41 crore for the fourth quarter that ended on March 31, 2014.

• Glenmark receives $4 million from Forest Lab as research fee

  The company through its Swiss unit has received $4 million as research fee payment from Forest Laboratories Inc for the development of novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain, it said.

• 

  Ranbaxy faces more regulatory scrutiny after US ban

  Ranbaxy Laboratories Ltd has been hit by more regulatory scrutiny sparked by a US ban on the bulk of its drugs, in a backlash that could bump up compliance costs and erode profitability among some Indian makers of generic drugs.

• Glenmark faces patent infringement suit for cancer drug in US

  The complaint has been filed against Glenmark trying to commercialise the product before the expiry of patent which is a generic version of Treanda, it added.

• Glenmark gets USFDA nod for skin infections cream

  Glenmark Generics Inc USA, the subsidiary of Glenmark Generics Ltd has received nod for its Hydrocortisone Butyrate Cream USP (0.1 per cent), abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (USFDA), Glenmark Pharmaceuticals said in a statement.

• Glenmark gets USFDA nod for alcohol abstinence drug

  Glenmark Generics Inc, the US-based subsidiary of Glenmark Generics Ltd (GGL), has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (USFDA) for Acamprosate Calcium Delayed Release Tablets, Glenmark Pharma said in a statement.

• UCB files cases against Ranbaxy, Aurobindo, Glenmark, others

  According to a petition filed by UCB Inc, UCB Pharma GMBH, Research Corporation Technologies, Inc and Harris FRC Corporation the patent of its drug Lacosamide Tablets, 50 mg, 100 mg, 150 mg and 200 mg would expire on March 17, 2022.